168 related articles for article (PubMed ID: 15997420)
1. Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study.
Olszynski WP; Davison KS; Ioannidis G; Brown JP; Hanley DA; Josse RG; Murray TM; Papaioannou A; Sebaldt RJ; Tenenhouse AM; Petrie A; Goldsmith CH; Adachi JD
Osteoporos Int; 2006 Feb; 17(2):217-24. PubMed ID: 15997420
[TBL] [Abstract][Full Text] [Related]
2. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
Sawka AM; Ioannidis G; Papaioannou A; Thabane L; Olszynski WP; Brown JP; Hanley DA; Murray TM; Josse RG; Sebaldt RJ; Petrie A; Tenenhouse A; Goldsmith CH; Boulos P; Kouroukis T; Adachi JD
J Obstet Gynaecol Can; 2005 Aug; 27(8):759-64. PubMed ID: 16287007
[TBL] [Abstract][Full Text] [Related]
3. Response to alendronate in osteoporosis after previous treatment with etidronate.
Fairney A; Kyd P; Thomas E; Wilson J
Osteoporos Int; 2000; 11(7):621-5. PubMed ID: 11069197
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2005 Dec; 46(6):750-8. PubMed ID: 16385649
[TBL] [Abstract][Full Text] [Related]
5. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
Hejdova M; Palicka V; Kucera Z; Vlcek J
Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879
[TBL] [Abstract][Full Text] [Related]
6. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database.
Papaioannou A; Ioannidis G; Adachi JD; Sebaldt RJ; Ferko N; Puglia M; Brown J; Tenenhouse A; Olszynski WP; Boulos P; Hanley DA; Josse R; Murray TM; Petrie A; Goldsmith CH
Osteoporos Int; 2003 Oct; 14(10):808-13. PubMed ID: 14523610
[TBL] [Abstract][Full Text] [Related]
7. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
Cortet B; Béra-Louville A; Gauthier P; Gauthier A; Marchandise X; Delcambre B
Joint Bone Spine; 2001 Oct; 68(5):410-5. PubMed ID: 11707007
[TBL] [Abstract][Full Text] [Related]
9. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.
Sebaldt RJ; Ioannidis G; Adachi JD; Bensen WG; Bianchi F; Cividino A; Gordon M; Kaminska E; Scocchia T; Petrie A; Stephenson GF; Goldsmith CH
J Rheumatol; 1999 Jul; 26(7):1545-9. PubMed ID: 10405943
[TBL] [Abstract][Full Text] [Related]
10. Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
Beauchesne MF; Miller PF
Ann Pharmacother; 1999 May; 33(5):587-99. PubMed ID: 10369624
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
12. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
13. COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy.
Qureshi AM; Herd RJ; Blake GM; Fogelman I; Ralston SH
Calcif Tissue Int; 2002 Mar; 70(3):158-63. PubMed ID: 11907712
[TBL] [Abstract][Full Text] [Related]
14. Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis.
Crilly RG; Sebaldt RJ; Hodsman AB; Adachi JD; Brown JP; Goldsmith CH; Hanley DA; Olszynski WO; Ste-Marie LG; Stephenson GF
Osteoporos Int; 2000; 11(7):607-14. PubMed ID: 11069195
[TBL] [Abstract][Full Text] [Related]
15. Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
Shimon I; Eshed V; Doolman R; Sela BA; Karasik A; Vered I
Osteoporos Int; 2005 Dec; 16(12):1591-6. PubMed ID: 16362147
[TBL] [Abstract][Full Text] [Related]
16. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?
Lems WF; Jacobs JW; Bijlsma JW; van Veen GJ; Houben HH; Haanen HC; Gerrits MI; van Rijn HJ
Ann Rheum Dis; 1997 Jun; 56(6):357-63. PubMed ID: 9227164
[TBL] [Abstract][Full Text] [Related]
17. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
Buckley LM; Hillner BE
J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
[TBL] [Abstract][Full Text] [Related]
18. Are there differences between men and women prescribed bisphosphonate therapy in canadian subspecialty osteoporosis practices?
Sawka AM; Adachi JD; Papaioannou A; Thabane L; Ioannidis G; Davison KS; Olszynski WP; Brown JP; Hanley DA; Murray TM; Josse RG; Sebaldt RJ; Petrie A; Tenenhouse A; Goldsmith CH
J Rheumatol; 2004 Oct; 31(10):1993-5. PubMed ID: 15468365
[TBL] [Abstract][Full Text] [Related]
19. A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
Sahota O; Fowler I; Blackwell PJ; Lawson N; Cawte SA; San P; Masud T; Hosking DJ
Osteoporos Int; 2000; 11(11):959-66. PubMed ID: 11193249
[TBL] [Abstract][Full Text] [Related]
20. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
